Table 3 Multivariate analysis of BAALC... | American Society of Hematology

Table 3

Multivariate analysis of BAALC expression for clinical outcome in BCR-ABL⁻ and MLL-AF4⁻ patients

Variable	HR	OR	95% CI	P
Refractory disease*
BAALC expression, T1 vs T2 vs T3		4.2	1.4-12.3	.01
Immunophenotype				.01‡
Common vs pre-B		1.0	0.1-9.1	.98
Pro-B vs pre-B		14	1.1-176	.04
Overall survival*†
BAALC expression, T1 vs T2 vs T3	1.4		1.0-2.0	.03
WBC more than 30 × 10⁹/L	3.9		2.2-6.9	< .001
Age, 10-year increase	1.5		1.3-1.8	< .001

Variable	HR	OR	95% CI	P
Refractory disease*
BAALC expression, T1 vs T2 vs T3		4.2	1.4-12.3	.01
Immunophenotype				.01‡
Common vs pre-B		1.0	0.1-9.1	.98
Pro-B vs pre-B		14	1.1-176	.04
Overall survival*†
BAALC expression, T1 vs T2 vs T3	1.4		1.0-2.0	.03
WBC more than 30 × 10⁹/L	3.9		2.2-6.9	< .001
Age, 10-year increase	1.5		1.3-1.8	< .001

HR indicates hazard ratio; and OR, odds ratio.

Variables considered for model inclusion are described in "Statistical analyses." The final model is shown.

Patients who received SCT in CR1 were censored at the time of transplantation.

Overall P value for the variable immunophenotype.